Researchers at the University of Cologne’s Center for Molecular Medicine Cologne (CMMC) report that KRAS-driven pancreatic tumors become dependent on caspase-8 and can be pushed into necroptosis with caspase-8 inhibition. The work, published in Nature Communications, ties oncogenic KRAS to type I interferon signaling that primes tumors through upregulation of necroptosis-associated pathways. In genetically engineered mouse models, caspase-8 deletion within KRAS-driven pancreatic lesions triggered widespread necroptotic cell death and reduced precursor lesions. The authors also reported tumor-burden reductions in aggressive PDAC models and patient-derived tumor organoids using pharmacologic caspase inhibition. For translational development, the study suggests a biomarker-driven vulnerability in subsets of KRAS-mutant PDAC, positioning the caspase-8 axis as a potential therapeutic strategy beyond classic KRAS targeting.